Rezolute Inc RZLT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
-
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
-
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
-
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
-
Rezolute to Participate in Upcoming Investor Conferences
-
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
-
Rezolute Says It Had Encouraging FDA Meeting on Congenital Hyperinsulinism Drug Despite Missed Endpoint
Trading Information
- Previous Close Price
- $3.90
- Day Range
- $3.56–3.99
- 52-Week Range
- $1.07–11.46
- Bid/Ask
- $3.60 / $4.19
- Shares Outstanding
- 96.72M
- Market Cap
- $346.27M
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 58
- Website
- https://www.rezolutebio.com
Valuation
|
Metric
|
RZLT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.41 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
RZLT
Financial Strength
|
Metric
|
RZLT
|
|---|---|
Quick Ratio | 9.44 |
Current Ratio | 9.68 |
Interest Coverage | — |
Quick Ratio
RZLT
Profitability
|
Metric
|
RZLT
|
|---|---|
Return on Assets (Normalized) | −44.39% |
Return on Equity (Normalized) | −48.20% |
Return on Invested Capital (Normalized) | −51.80% |
Return on Assets
RZLT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|N<w<tL# | LOCK|v$P&N | $127B | |||
| Moderna Inc
MRNA
| LOCK|QVqg$< | LOCK|g! | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|WgV<b<^ | LOCK|y?s! | $81B | |||
| argenx SE ADR
ARGX
| LOCK|VW$kD$$ | LOCK|b?h | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<W^#@>! | LOCK|^& | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|kPbvS> | LOCK|FZJ%F | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|D@##KtXh | LOCK|>rK^> | $27B | |||
| Incyte Corp
INCY
| LOCK|<T!ql< | LOCK|k< | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|>$fL#Rr | LOCK|G@ | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|tH$$S?b | LOCK|Wn | $14B |
United States